Abstracts

RESIDENT MEMORY CD8+ T CELLS FORM THE FRONT-LINE DEFENSE IN HIV-INFECTED LYMPH NODES

CD8+ T cells are key players in HIV control and future cure efforts. Current knowledge of HIV-specific CD8+ T cells relies almost entirely on circulating cells, although HIV is primarily a disease of lymphoid tissue. Accumulating evidence indicates that non-circulating ‘resident memory’ (TRM) CD8+ T cell responses are critical for pathogen control in tissues; however,…

HIV-1 ESCAPE FROM CD8+ CYTOTOXIC T-LYMPHOCYTES DEFINED AT CLONAL RESOLUTION

A small number of HIV-infected individuals are able to effectively suppress HIV replication without antiretroviral therapy. Certain ‘protective’ HLA types correlate with this ability to suppress HIV replication, indicating that the CD8+ cytotoxic T-lymphocyte (CTL) response in these individuals is responsible for the efficient containment of HIV. However, the mechanism behind CTL mediated control is…

INVESTIGATING THE ROLE OF TCR STRUCTURE IN FUNCTIONAL ACTIVITY OF HIV-SPECIFIC CTLs

Lentiviral vectors expressing effective HIV-specific TCR clonotypes can transform naïve CD8+ T cells into potent HIV-specific CTLs, a possible gene therapy approach to increase HIV-specific immunity. To optimize this approach, it is crucial to identify TCR clonotypes which confer the most potent anti-HIV activity. CTLs with superior antiviral efficacy, termed effective CTLs, are well-represented in…

TREATMENT OF ACUTE HIV INFECTION IN NEONATES

Antiretroviral therapy (ART) initiated soon after primary infection is thought to influence seeding of the viral reservoir with beneficial effects for virologic control. Infants are an important group who can be identified soon after infection. Here we describe virologic dynamics following early ART in infants. For the past 2 years, HIV PCR testing has been…

LOPINAVIR/RITONAVIR 1:1 SUPER-BOOSTING OVERCOMES RIFAMPICIN INTERACTIONS IN CHILDREN

Lopinavir/ritonavir 4:1 (LPV/r) is important in 1st-line antiretroviral therapy for infants. In high-burden settings, rifampicin based co-treatment for tuberculosis (TB) is often needed, but causes significant drug interactions. Superboosting LPV/r with ritonavir for a 1:1 ratio is considered effective, based on pharmacokinetic (PK) studies in 15 children. In an open-label, prospective study at 5 South…